FY2026 Earnings Forecast for Vericel Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS forecast for Vericel to $0.79 from $0.45, versus a consensus estimate of $0.54. The firm maintains a Buy rating and a $75 price target.
• Vericel reported quarterly EPS of $0.27, beating the $0.06 consensus, while revenue of $85.37 million topped estimates of $77.95 million and rose 26.5% year over year.
• Analyst sentiment is broadly positive: MarketBeat reports a Moderate Buy consensus and an average price target of $60.80.

Vericel Corporation (NASDAQ:VCEL - Free Report) - Analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Vericel in a research note issued on Friday, November 6th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn $0.79 per share for the year, up from their previous forecast of $0.45. HC Wainwright currently has a "Buy" rating and a $75.00 target price on the stock. The consensus estimate for Vericel's current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for Vericel's Q1 2027 earnings at $0.02 EPS, Q2 2027 earnings at $0.18 EPS, Q3 2027 earnings at $0.15 EPS and FY2027 earnings at $0.89 EPS.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.21. The business had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. Vericel had a return on equity of 6.91% and a net margin of 7.91%. Vericel's quarterly revenue was up 26.5% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share.

A number of other equities research analysts have also recently commented on VCEL. TD Cowen lifted their target price on Vericel from $55.00 to $58.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Truist Financial raised their price objective on shares of Vericel from $52.00 to $65.00 and gave the stock a "buy" rating in a report on Friday. Weiss Ratings restated a "hold (c)" rating on shares of Vericel in a report on Thursday, October 29th. Canaccord Genuity Group set a $60.00 price objective on shares of Vericel in a research report on Thursday, July 30th. Finally, Wall Street Zen upgraded shares of Vericel from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $60.80.

Vericel Price Performance

Shares of NASDAQ:VCEL opened at $58.39 on Tuesday. The company has a market capitalization of $2.99 billion, a PE ratio of 91.24 and a beta of 1.08. The business has a fifty day moving average price of $41.36 and a two-hundred day moving average price of $39.00. Vericel has a 1 year low of $28.95 and a 1 year high of $59.48.

Insider Buying and Selling at Vericel

In other news, insider Sean C. Flynn sold 15,000 shares of Vericel stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $51.92, for a total value of $778,800.00. Following the completion of the transaction, the insider directly owned 1,990 shares in the company, valued at approximately $103,320.80. The trade was a 88.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert L. Md Zerbe sold 3,000 shares of the business's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $52.23, for a total value of $156,690.00. Following the sale, the director owned 32,995 shares in the company, valued at approximately $1,723,328.85. The trade was a 8.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 22,000 shares of company stock valued at $1,128,340 over the last three months. 7.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vericel

Several hedge funds and other institutional investors have recently modified their holdings of VCEL. Intech Investment Management LLC lifted its holdings in shares of Vericel by 41.7% in the third quarter. Intech Investment Management LLC now owns 91,026 shares of the biotechnology company's stock worth $3,654,000 after buying an additional 26,790 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in Vericel by 24.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,194 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 237 shares during the period. Virtus Advisers LLC lifted its stake in Vericel by 77.7% in the 3rd quarter. Virtus Advisers LLC now owns 27,661 shares of the biotechnology company's stock worth $1,110,000 after purchasing an additional 12,091 shares in the last quarter. Aberdeen Group plc lifted its stake in Vericel by 204.7% in the 3rd quarter. Aberdeen Group plc now owns 2,164,250 shares of the biotechnology company's stock worth $86,873,000 after purchasing an additional 1,454,012 shares in the last quarter. Finally, Allworth Financial LP lifted its stake in Vericel by 53.0% in the 3rd quarter. Allworth Financial LP now owns 2,052 shares of the biotechnology company's stock worth $91,000 after purchasing an additional 711 shares in the last quarter.

Vericel Company Profile

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States.

Its products include MACI, an implant made from a patient's own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.

The company traces its roots to Aastrom Biosciences and adopted the Vericel name in 2014.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.